The Predictive Role of Preoperative Pentraxin-3 (PTX3) in Metabolic and Inflammatory Outcomes After Roux-en-Y Gastric Bypass (PTX3-BYPASS)

Istanbul University

Status: Completed

Conditions: Inflammation; Roux en Y Gastric Bypass; Chronic Inflammation; Insulin Resistance; C-Reactive Protein; Obesity; Interleukin-6; Metabolic Syndrome

Treatments: Other: Biomarker Stratification by PTX3

Study type: Observational

Funder types: Other

Identifiers

NCT07241741

ITF_2025_09

Details and patient eligibility

About

This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.

Full description

This single-center longitudinal study was conducted at Istanbul University Hospital. A total of 23 patients undergoing primary Roux-en-Y gastric bypass were included. PTX3 levels were measured preoperatively, and patients were stratified according to a data-derived cut-off (~21.7 ng/mL). Outcomes assessed at baseline, 3 months, and 6 months included body weight, BMI, excess weight loss (%EWL), fasting insulin, HOMA-IR, CRP, and IL-6. The primary hypothesis was that preoperative PTX3 would predict postoperative CRP normalization and insulin resistance improvement.

Enrollment: 23 patients

Sex: All

Ages: 18 to 65 days old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 18-65 years
• Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity
• Eligible for primary Roux-en-Y gastric bypass
• Able to provide written informed consent

Exclusion criteria

• Previous bariatric surgery
• Severe hepatic, renal, or cardiac failure
• Active infection or inflammatory disease
• Malignancy

Trial design

23 participants in 2 patient groups

Group 1: High PTX3 (≥21.7 ng/mL)

Description:

Participants with preoperative serum PTX3 levels ≥21.7 ng/mL. All patients underwent Roux-en-Y gastric bypass and were followed prospectively for 6 months with metabolic and inflammatory assessments.

Treatment:

Other: Biomarker Stratification by PTX3

Group 2: Low PTX3 (<21.7 ng/mL)

Description:

Participants with preoperative serum PTX3 levels \<21.7 ng/mL. All patients underwent Roux-en-Y gastric bypass and were followed prospectively for 6 months with metabolic and inflammatory assessments.

Treatment:

Other: Biomarker Stratification by PTX3